Selank is a synthetic heptapeptide derived from the immunopeptide tuftsin that has been studied as a candidate anxiolytic. This article reviews how experimental models describe its interaction with the GABAergic system, and how far that evidence actually extends.

What Selank is, and the research question

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide built on the tetrapeptide tuftsin, extended at the C-terminus by a Pro-Gly-Pro sequence. It has been investigated in Russian pharmacology programs as a peptide anxiolytic with an unusually broad reported profile that spans anti-anxiety, nootropic, and immunomodulatory readouts.² Because classical anxiolytics such as benzodiazepines act through the GABA_A receptor, a central research question has been whether Selank engages the same inhibitory neurotransmitter system, and if so, through what kind of interaction.

The literature approaches this question from three complementary directions: radioligand binding assays that probe the receptor directly, gene-expression profiling that captures downstream transcriptional responses, and behavioral assays in validated rodent anxiety paradigms. Each layer is informative, and each carries its own limitations. The sections below summarize what the primary literature reports, and where it stops short.

For context on how researchers frame Selank alongside other GABA-active compounds, one 2021 pharmacology review grouped it with agents that "share a gamma-aminobutyric acid (GABA) receptor-related mechanism of action," while explicitly noting that Selank remains poorly studied relative to established drugs.¹⁰

Structural basis for a GABAergic interaction

Selank's proposed mode of receptor engagement is tied to its peptide architecture. The Thr-Lys-Pro-Arg core is the tuftsin-derived element, while the Pro-Gly-Pro extension is generally described as improving proteolytic stability and prolonging persistence in experimental systems relative to the parent tetrapeptide.⁷ This scaffold is consistent with a non-competitive, modulatory interaction rather than the orthosteric binding characteristic of GABA itself.

Several structural attributes are commonly cited as relevant to this interaction:

• The Thr-Lys-Pro-Arg tuftsin core, which anchors the reported peptide-receptor association.
• The Pro-Gly-Pro (glyproline) extension, associated with resistance to peptidase cleavage and a longer functional window in tissue.⁷
• An all-L-amino-acid configuration compatible with an accessory, non-orthosteric receptor region.

Taken together, these features frame Selank as a modulator that stabilizes receptor conformations rather than a ligand that occupies the GABA binding pocket. That framing is a hypothesis grounded in binding data, discussed next, not a settled structural model; no high-resolution structure of a Selank-receptor complex has been reported.

Positive allosteric modulation of GABA_A: the binding evidence

The most direct mechanistic evidence comes from radioligand-receptor experiments in isolated rat brain plasma membranes. In this work, Selank altered [³H]GABA-specific binding in a manner consistent with positive allosteric modulation, increasing bound ligand without behaving as an orthosteric agonist.² The authors reported that the combined action of Selank with certain benzodiazepines was not simply additive and differed from either compound alone, and that Selank could block the modulatory activity of diazepam and olanzapine.²

An important nuance is frequently misread. The same study concluded that the peptide and benzodiazepine binding sites are "apparently not the same, but potentially may partially overlap."² In other words, the data support an allosteric mechanism distinct from classical benzodiazepine action, but they do not cleanly establish a fully independent, non-overlapping site. The overall interpretation offered by the investigators is a subtype-selective, concentration-dependent allosteric modulation of GABA receptors.²

This binding-level picture is the anchor of the whole mechanistic story. Everything downstream, gene expression and behavior, is consistent with it but does not, on its own, prove receptor-level causation.

GABAergic gene expression across cortical networks

Beyond direct binding, researchers have asked whether Selank leaves a transcriptional signature in inhibitory circuitry. In rat frontal cortex, a single administration of Selank (or of GABA, as a comparator) was followed by real-time PCR profiling of 84 neurotransmission-related genes. Significant expression changes were detected in 45 genes at one hour and in 22 genes at three hours, with a positive correlation between the Selank- and GABA-induced changes at the one-hour timepoint.¹ The authors interpreted this rapid, broad response as compatible with allosteric modulation of the GABAergic system.¹

Three features of this dataset are worth isolating:

• Breadth. The affected genes spanned GABA receptor subunits, transporters, ion channels, and monoamine receptors, indicating that the transcriptional response is not confined to a single gene family.¹
• Speed. Changes were measurable within one hour, pointing to early genomic engagement that precedes any downstream network-level or behavioral observation.¹
• Convergence with GABA. The correlation between Selank- and GABA-driven expression patterns is the transcriptional thread linking the peptide to inhibitory signaling.¹

The table below summarizes how the main experimental approaches differ in what they can and cannot establish.

Where the evidence disagrees

Honest mechanistic reporting requires flagging the negative and discordant results, not only the supportive ones. When Selank was applied to cultured IMR-32 neuroblastoma cells and the expression of 84 GABAergic-system genes was measured by qPCR, the investigators found no changes in mRNA levels under Selank alone.⁴ Effects appeared only in combination conditions: co-application with GABA suppressed GABA-driven changes, and co-application with olanzapine altered more genes than olanzapine by itself.⁴

The authors read this as partial support for the hypothesis that the peptide modulates the interaction of GABA with its receptors, rather than acting directly on transcription in an isolated cell.⁴ The practical lesson is that the transcriptional footprint seen in intact rat cortex¹ may depend on circuit-level context that a single cell line does not reproduce. Any claim that Selank "changes GABAergic gene expression" should therefore be qualified by model system: robust in vivo, absent in this in vitro preparation without a co-agonist.

GABA-monoamine crosstalk and behavioral readouts

Selank's reported behavioral profile does not map onto GABA alone. Early work characterized a monoaminergic component, describing activation of brain monoaminergic systems and effects on dopamine synthesis and turnover, alongside antidepressant-like and psychostimulant-like readouts in rodent models.⁶ This positions the peptide at an intersection of inhibitory and monoaminergic signaling rather than as a narrow GABA_A modulator.

Behavioral correlates

In the elevated plus maze under unpredictable chronic mild stress, Selank administration was associated with changes in anxiety-related indices, and the combination of Selank with diazepam produced the most pronounced return of anxiety measures toward pre-stress values in that paradigm.³ Separately, individual Selank administration was reported as most active at reducing elevated anxiety induced by the test course itself.³ A key distinction repeatedly emphasized is that these anxiolytic-type effects were observed without the locomotor suppression typical of sedative agents.⁶

Stress-model sensitivity and neurotrophic signals

Effects tend to be more pronounced under stress. In restraint-stress models, Selank reduced elevated corticosterone and attenuated pathomorphological stress signs,¹² and under "social" stress it lowered pro-inflammatory cytokines toward control levels.¹¹ A separate line of work implicates brain-derived neurotrophic factor (BDNF): in a chronic-ethanol rat model, Selank modulated BDNF content in the hippocampus and prefrontal cortex alongside preserved recognition memory.⁸ The peptide has also been reported to attenuate aversive signs of naloxone-precipitated morphine withdrawal, with potency somewhat below diazepam in that model.⁹ Collectively these findings suggest convergent stress-responsive pathways rather than a single receptor acting in isolation. Researchers comparing peptide neuromodulators sometimes examine Selank alongside related compounds such as Semax, which shares the same laboratory lineage but a distinct reported profile.

Human data, evidence level, and regulatory status

Human evidence exists but is thin. A comparative clinical study in 62 patients with generalized anxiety disorder and neurasthenia compared Selank with the benzodiazepine medazepam and reported broadly similar anxiolytic effects, plus additional anti-asthenic and psychostimulant effects and a correlated change in an enkephalin biomarker.⁵ This is a small, single-program study published in 2008; it is a supportive signal, not a robust, independently replicated efficacy demonstration, and it does not establish safety at the standard expected of an approved medicine.

The honest summary is a coherent but incomplete mechanistic picture: allosteric interaction with GABA_A receptors,² a rapid cortical transcriptional response,¹ monoaminergic and neurotrophic involvement,⁶⁸ and anxiety-related behavioral shifts in stress models³ — tempered by discordant in vitro data⁴ and limited human validation. Regulatory reviews additionally note that Selank has not completed the clinical-trial pathway of an approved drug in Western jurisdictions and is sometimes mislabeled in the consumer market.¹⁰ For laboratories, the material remains a well-defined tool for probing GABAergic and monoaminergic mechanisms, not a therapeutic.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.